Can Hormone Replacement Therapy Prevent Gout? What the Research Actually Shows

HRT Lowers Uric Acid. Does That Mean It Can Prevent Gout?

If you went through menopause and your uric acid crept up, you might have wondered: could hormone replacement therapy (HRT) bring it back down? After all, estrogen helps your kidneys flush out uric acid. When estrogen drops after menopause, uric acid rises. So could replacing estrogen fix the problem?

The short answer: HRT does lower uric acid, but only modestly. And the risks of taking HRT solely for gout prevention far outweigh the benefits. Here is what the research actually shows.

How Estrogen Protects Against Gout Before Menopause

Estrogen does something useful: it signals your kidneys to excrete more uric acid. Before menopause, women typically have uric acid levels 1 to 1.5 mg/dL lower than men of the same age. This is why women rarely develop gout before menopause.

But after menopause, estrogen production drops sharply. Kidneys lose their uric acid-clearing boost. Serum uric acid climbs, and with it, the risk of gout. Over 80% of women who develop gout are postmenopausal. We covered this transition in detail in our article on what happens when estrogen disappears.

This raises a logical question: if losing estrogen raises uric acid, could taking estrogen (via HRT) bring it back down?

NHANES III: HRT Users Had Lower Uric Acid

The first large-scale evidence came from the Third National Health and Nutrition Examination Survey (NHANES III), which included 7,662 women in the United States. Researchers Hak and Choi found that postmenopausal women currently using hormone therapy had serum uric acid levels 0.24 mg/dL lower than women who had not used hormone therapy, after adjusting for age, body mass index, kidney function, diet, and other confounders.

Past users also showed a benefit: 0.15 mg/dL lower than non-users. The effect held steady across different body weights, blood pressure levels, and drinking habits.

To put 0.24 mg/dL in perspective: it is roughly the difference between eating a moderate-purine meal and skipping it. Helpful, but not dramatic. For comparison, the uric acid increase from menopause itself was 0.34 mg/dL for natural menopause and 0.36 mg/dL for surgical menopause.

The HERS Trial: E+P Lowered Uric Acid by 0.2 mg/dL

The Heart and Estrogen-Progestin Replacement Study (HERS), published in the Annals of Epidemiology in 2006, provided experimental data. Researchers randomly assigned 2,763 postmenopausal women with coronary disease to either conjugated estrogen plus progestin (E+P) or placebo.

After one year, the treatment group had uric acid levels 0.2 mg/dL lower than placebo. The result was statistically significant (p<0.0001). But here is the twist: baseline uric acid was associated with coronary heart disease events in simple models, but this association vanished after adjusting for other risk factors. And the change in uric acid from HRT had no bearing on heart outcomes.

In other words, HRT moved the uric acid needle, but the movement was too small to change cardiovascular outcomes. Given that women with gout face nearly double the cardiovascular risk, this matters.

The UK Study: HRT Reduced Gout Risk by 31%

The most direct evidence on HRT and gout comes from a UK population-based case-control study published in Menopause in 2015. Bruderer and colleagues analyzed records from the Clinical Practice Research Datalink, identifying women aged 45 and older with a first-time gout diagnosis between 1990 and 2010.

Their key finding: women currently using oral estrogen-progestogen therapy (combined HRT) had a 31% lower odds of developing gout compared to non-users (adjusted OR 0.69, 95% CI 0.56 to 0.86). The protective effect was even stronger in women with hypertension: a 38% reduction in gout odds (OR 0.62, 95% CI 0.44 to 0.87).

Tibolone, a synthetic steroid with estrogenic, progestogenic, and weak androgenic activity, was also associated with lower gout odds (OR 0.77, 95% CI 0.63 to 0.95).

The Progestogen Puzzle: It Might Not Be Estrogen Doing the Work

Here is where the story gets more complicated. In the same UK study, unopposed estrogen (estrogen alone, without progestogen) had no effect on gout risk. The odds ratio was not statistically different from no use.

This suggests the gout-protective effect might come from the progestogen component rather than the estrogen. That flips the conventional narrative. People assumed estrogen was the hero because of its known uric acid-lowering effect. But the data points to progestogens doing some of the heavy lifting.

The mechanism is not fully understood. Progestogens may affect urate transporters in the kidney differently than estrogen. Or the combination of estrogen plus progestogen may trigger a metabolic pathway that neither hormone activates alone.

HRT Might Counteract Diuretic-Induced Uric Acid Spikes

A 2019 study from Poland added another piece to the puzzle. Researchers studied hypertensive postmenopausal women treated with either hydrochlorothiazide (a thiazide diuretic) or an ACE inhibitor, with or without estrogen-progestin therapy.

Thiazide diuretics are notorious for raising uric acid. As we discussed in our article on diuretics and women’s gout, this is a particular problem for women, who are prescribed diuretics more often than men.

In the study, women taking hydrochlorothiazide without hormone therapy saw their uric acid rise significantly after 12 months. But women taking hydrochlorothiazide plus estrogen-progestin therapy actually saw their uric acid decrease compared to baseline. The hormone therapy appeared to reverse the uric acid-raising effect of the diuretic.

For women on ACE inhibitors, uric acid stayed stable regardless of hormone therapy. This suggests the benefit of HRT was specific to counteracting the thiazide damage.

Why HRT Is Not a Gout Prevention Strategy

So HRT lowers uric acid and reduces gout risk. Should every postmenopausal woman take it to prevent gout? No. Here is why.

The Women’s Health Initiative (WHI), the largest randomized trial of HRT ever conducted, found that combined estrogen plus progestin increased the risk of:

• Breast cancer (risk rises with duration, more pronounced after 5 years of use)
• Blood clots (venous thromboembolism risk roughly doubled with oral estrogen)
• Stroke (ischemic stroke risk increased about 28% with oral estrogen)

In late 2025, the FDA began removing the “black box” warning from HRT products, citing reanalysis showing that risks are concentrated in women who start HRT more than 10 years after menopause. For women who start earlier, the risk profile is more favorable. But the risks have not disappeared.

The U.S. Preventive Services Task Force recommends against using HRT for chronic disease prevention. The 2022 position statement from The Menopause Society says the same thing: HRT is for symptom relief, not for preventing long-term conditions.

Using HRT to lower uric acid by 0.2 mg/dL when allopurinol can lower it by 3 to 5 mg/dL or more makes no clinical sense. You would be accepting real risks for a benefit that standard gout medications deliver many times over.

Timing Changes Everything

If a woman is already taking HRT for menopausal symptoms (hot flashes, night sweats, vaginal dryness), the uric acid benefit is a bonus, not a reason to start. And timing matters.

The “timing hypothesis” suggests that starting HRT within 10 years of menopause or before age 60 is associated with cardiovascular benefits. Starting later may increase cardiovascular risk. This is now the organizing principle of HRT safety thinking worldwide.

For women with elevated gout risk who are considering HRT for symptom relief, transdermal delivery (patches, gels) is preferred over oral tablets. Transdermal estrogen does not increase blood clot risk, while oral estrogen does. The 2022 Menopause Society guidelines and 2024 Korean guidelines favor transdermal estradiol at low to moderate doses when cardiovascular or thrombotic risk is a concern.

What Should You Actually Do?

If you are postmenopausal and worried about gout, here is what the evidence supports:

1. Check your uric acid. The target for women is below 6 mg/dL (360 micromol/L). If you have tophi or frequent flares, the target is below 5 mg/dL (300 micromol/L). As we noted in our coverage of menopause and gout risk, your 50s are a turning point.

2. If you need HRT for menopausal symptoms, do not stop because of gout concerns. The uric acid-lowering effect is a modest bonus. But do not start HRT for gout prevention alone.

3. Ask about transdermal delivery. If you are taking or considering HRT, patches and gels carry less clot and stroke risk than oral tablets.

4. Review your medications. If you are on thiazide diuretics for blood pressure, talk to your doctor about alternatives. Losartan has mild uric acid-lowering effects. SGLT2 inhibitors lower both blood sugar and uric acid.

5. Get to target with proven therapy. Allopurinol and febuxostat are the real tools for lowering uric acid. You can read more about how they compare in our article on allopurinol versus febuxostat. HRT might shave off 0.2 mg/dL. These medications can drop your uric acid by 3 to 5 mg/dL or more.

The Bottom Line

HRT does lower uric acid in postmenopausal women. The effect is real and consistent across multiple studies. But it is small: about 0.2 to 0.24 mg/dL. That is not enough to prevent gout in someone whose uric acid is already high.

The 31% reduction in gout risk found in the UK study sounds impressive, but it reflects the difference between women who happen to take HRT and women who do not. It does not mean HRT is a gout treatment. Women who take HRT tend to be younger, healthier, and more health-conscious, factors that independently lower gout risk.

If you are already on HRT for menopausal symptoms, enjoy the small uric acid benefit. If you are not on HRT and your main concern is gout, talk to your doctor about urate-lowering therapy. The evidence is clear: allopurinol works, it is affordable, and it does not carry the risks that HRT does.

Frequently Asked Questions

Does HRT lower uric acid levels?

Yes. Multiple studies, including NHANES III and the HERS trial, show that HRT lowers serum uric acid by approximately 0.2 to 0.24 mg/dL in postmenopausal women. The effect is statistically significant but modest compared to standard urate-lowering medications like allopurinol.

Can HRT be used to treat gout?

No. HRT is not approved or recommended for gout treatment. The uric acid reduction from HRT is too small to serve as a therapeutic strategy. Allopurinol and febuxostat are far more effective and are the standard first-line options for lowering uric acid.

Does estrogen alone protect against gout, or do you need combination therapy?

Research suggests combination therapy (estrogen plus progestogen) may be more protective than estrogen alone. In the UK case-control study, combined HRT was associated with 31% lower gout odds, while estrogen alone had no significant effect. The progestogen component may play a role that researchers are still working to understand.

What are the main risks of taking HRT?

The main risks include increased chances of breast cancer (with combined therapy after 5 years of use), blood clots (roughly doubled with oral estrogen), and stroke (about 28% higher with oral estrogen). Transdermal HRT carries less risk. Starting HRT within 10 years of menopause or before age 60 is associated with a better safety profile, according to the “timing hypothesis.”

If I have gout and am on diuretics, should I consider HRT?

Not for gout prevention specifically. But the Polish study showing that HRT reversed thiazide-induced uric acid elevation is worth discussing with your doctor if you are already considering HRT for menopausal symptoms. A better approach is to ask your doctor about switching from a thiazide diuretic to a blood pressure medication that does not raise uric acid, such as losartan.

Reviewed by the GoutSavvy Editorial Team